ORIGINAL RESEARCH article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1595096
This article is part of the Research TopicMucosal Immunity after VaccinationView all 4 articles
Construction and Evaluation of a Salmonella Minicell-Based Dendritic Cell-Targeted Multi-Epitope Vaccine Against Helicobacter pylori
Provisionally accepted
- 1Sichuan University, Chengdu, China
- 2West China Fourth Hospital of Sichuan University, Chengdu, Sichuan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Helicobacter pylori (H. pylori) infection is a global health concern linked to various gastrointestinal diseases, highlighting the urgent need for effective vaccines. In this study, we developed two multiepitope vaccine candidates based on Salmonella minicells: TA-2m and Apt-TA-2m. Apt-TA-2 is an advanced formulation of TA-2m, coated with dendritic cell-targeting RNA aptamer to enhance antigen delivery and immune activation. The physical properties of the vaccines, including shape, size, particle dispersion index (PDI), and zeta potential, were characterized using transmission electron microscopy (TEM) or dynamic light scattering (DLS). Comprehensive in vitro and in vivo evaluations were conducted to assess their safety, immunogenicity, and protective efficacy. Both vaccines demonstrated excellent safety profiles and elicited strong immune responses, significantly reducing H. pylori colonization and alleviating gastric pathology. Notably, Apt-TA-2m demonstrated superior immunogenicity, characterized by enhanced T-cell cytokine production, increased mucosal IgA levels, and greater reductions in gastric bacterial loads. These findings underscore the potential of minicellbased vaccines for combating H. pylori infections. The enhanced protective efficacy of the Apt-TA-2m vaccine positions it as a promising candidate for further clinical development.
Keywords: Helicobacter pylori, Salmonella minicells, Vaccine Design, Immune efficacy, Multi-epitope, stomach cancer
Received: 17 Mar 2025; Accepted: 09 May 2025.
Copyright: © 2025 Yang, Chen, Zhu, Xie, Fang, Wang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chuan Wang, Sichuan University, Chengdu, China
Tian Tang, Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.